These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 2538359)
1. Drug targeting in Leishmania donovani infections using tuftsin-bearing liposomes as drug vehicles. Guru PY; Agrawal AK; Singha UK; Singhal A; Gupta CM FEBS Lett; 1989 Mar; 245(1-2):204-8. PubMed ID: 2538359 [TBL] [Abstract][Full Text] [Related]
2. Superior chemotherapeutic efficacy of amphotericin B in tuftsin-bearing liposomes against Leishmania donovani infection in hamsters. Agrawal AK; Agrawal A; Pal A; Guru PY; Gupta CM J Drug Target; 2002 Feb; 10(1):41-5. PubMed ID: 11996085 [TBL] [Abstract][Full Text] [Related]
3. Combination therapy using sodium antimony gluconate in stearylamine-bearing liposomes against established and chronic Leishmania donovani infection in BALB/c Mice. Pal S; Ravindran R; Ali N Antimicrob Agents Chemother; 2004 Sep; 48(9):3591-3. PubMed ID: 15328135 [TBL] [Abstract][Full Text] [Related]
4. Biodegradable microspheres: polyacryl starch microparticles as a delivery system for the antileishmanial drug, sodium stibogluconate. Baillie AJ; Coombs GH; Dolan TF; Hunter CA; Laakso T; Sjöholm I; Stjärnkvist P J Pharm Pharmacol; 1987 Oct; 39(10):832-5. PubMed ID: 2891821 [TBL] [Abstract][Full Text] [Related]
5. Vesicular systems (niosomes and liposomes) for delivery of sodium stibogluconate in experimental murine visceral leishmaniasis. Hunter CA; Dolan TF; Coombs GH; Baillie AJ J Pharm Pharmacol; 1988 Mar; 40(3):161-5. PubMed ID: 2899143 [TBL] [Abstract][Full Text] [Related]
6. The cured immune phenotype achieved by treatment of visceral leishmaniasis in the BALB/c mouse with a nonionic surfactant vesicular formulation of sodium stibogluconate does not protect against reinfection. Carter KC; Baillie AJ; Mullen AB Clin Diagn Lab Immunol; 1999 Jan; 6(1):61-5. PubMed ID: 9874665 [TBL] [Abstract][Full Text] [Related]
7. Tuftsin-bearing liposomes as antibiotic carriers in treatment of macrophage infections. Gupta CM; Haq W Methods Enzymol; 2005; 391():291-304. PubMed ID: 15721387 [TBL] [Abstract][Full Text] [Related]
8. Non-ionic surfactant vesicles, niosomes, as a delivery system for the anti-leishmanial drug, sodium stibogluconate. Baillie AJ; Coombs GH; Dolan TF; Laurie J J Pharm Pharmacol; 1986 Jul; 38(7):502-5. PubMed ID: 2875149 [TBL] [Abstract][Full Text] [Related]
9. Efficacies of vesicular and free sodium stibogluconate formulations against clinical isolates of Leishmania donovani. Carter KC; Mullen AB; Sundar S; Kenney RT Antimicrob Agents Chemother; 2001 Dec; 45(12):3555-9. PubMed ID: 11709339 [TBL] [Abstract][Full Text] [Related]
10. Visceral leishmaniasis: resistance to reinfection in the liver following chemotherapy in the BALB/c mouse. Carter KC; Alexander J; Baillie AJ; Dolan TF Exp Parasitol; 1989 May; 68(4):375-81. PubMed ID: 2542078 [TBL] [Abstract][Full Text] [Related]
11. Therapy with sodium stibogluconate in stearylamine-bearing liposomes confers cure against SSG-resistant Leishmania donovani in BALB/c mice. Roychoudhury J; Sinha R; Ali N PLoS One; 2011 Mar; 6(3):e17376. PubMed ID: 21423750 [TBL] [Abstract][Full Text] [Related]
12. Cationic liposomal sodium stibogluconate (SSG), a potent therapeutic tool for treatment of infection by SSG-sensitive and -resistant Leishmania donovani. Sinha R; Roychoudhury J; Palit P; Ali N Antimicrob Agents Chemother; 2015 Jan; 59(1):344-55. PubMed ID: 25367907 [TBL] [Abstract][Full Text] [Related]
13. Adjunct effect of immunostimulating hexapeptide analogous to human beta-casein fragment (54-59) to sodium stibogluconate against experimental visceral leishmaniasis. Gupta S; Srivastava VM; Puri A; Pandey D; Haq W Immunopharmacol Immunotoxicol; 2004 Aug; 26(3):425-34. PubMed ID: 15518175 [TBL] [Abstract][Full Text] [Related]
14. Genetic control of drug-induced recovery from murine visceral leishmaniasis. Carter KC; Baillie AJ; Alexander J J Pharm Pharmacol; 1993 Sep; 45(9):795-8. PubMed ID: 7903366 [TBL] [Abstract][Full Text] [Related]
15. Sub-optimal dose of Sodium Antimony Gluconate (SAG)-diperoxovanadate combination clears organ parasites from BALB/c mice infected with antimony resistant Leishmania donovani by expanding antileishmanial T-cell repertoire and increasing IFN-gamma to IL-10 ratio. Haldar AK; Banerjee S; Naskar K; Kalita D; Islam NS; Roy S Exp Parasitol; 2009 Jun; 122(2):145-54. PubMed ID: 19422069 [TBL] [Abstract][Full Text] [Related]
16. The therapeutic effect of sodium stibogluconate in BALB/c mice infected with Leishmania donovani is organ-dependent. Carter KC; Baillie AJ; Alexander J; Dolan TF J Pharm Pharmacol; 1988 May; 40(5):370-3. PubMed ID: 2899637 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of some drugs on Leishmania donovani in the golden hamster, Mesocricetus auratus. Al-Khateeb GH; Molan AL Chemotherapy; 1981; 27(2):117-25. PubMed ID: 6110518 [TBL] [Abstract][Full Text] [Related]
18. The sensitivity of Leishmania species to aminosidine. Neal RA; Allen S; McCoy N; Olliaro P; Croft SL J Antimicrob Chemother; 1995 May; 35(5):577-84. PubMed ID: 7592170 [TBL] [Abstract][Full Text] [Related]